Protective effect of the dopamine D3 receptor agonist (7-OH-PIPAT) against apoptosis in malignant peripheral nerve sheath tumor (MPNST) cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 927-934

  Castorina, A ^a   Giunta, S ^a   D'Agata, V ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apoptosis; Dopamine D3 receptor; Malignant peripheral nerve sheath tumor; Neurofibromin

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; NEUROFIBROMIN; TRANS 7 HYDROXY 2 [N PROPYL N' (3' IODO 2' PROPENYL)AMINO]TETRALIN MALEATE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNOFLUORESCENCE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NERVE SHEATH TUMOR; NEUROPROTECTION; NONHUMAN; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCHWANN CELL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPROTECTION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; NERVE SHEATH NEOPLASMS; NEUROFIBROMIN 1; RATS; RECEPTORS, DOPAMINE D3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 77956529778     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000743     Document Type: Article

References (31)

1. Upadhyaya M, Ruggieri M, Maynard J, et al: Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet 102: 591-597, 1998. (Pubitemid 28282590)
2. Upadhyaya M, Spurlock G, Kluwe L, et al: The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics 10: 251-263, 2009.
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E and Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39: 311-314, 2002.
4. Tucker T and Friedman JM: Pathogenesis of hereditary tumors: beyond the 'two-hit' hypothesis. Clin Genet 62: 345-357, 2002.
5. DeClue JE, Stone JC, Blanchard RA, Papageorge AG, Martin P, Zhang K and Lowy DR: A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1. Mol Cell Biol 11: 3132-3138, 1991.
6. Parada LF: Neurofibromatosis type 1. Biochim Biophys Acta 1471: M13-M19, 2000.
7. Shapira S, Barkan B, Friedman E, Kloog Y and Stein R: The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14: 895-906, 2007.
8. Giunta S, Castorina A, Adorno A, Mazzone V, Carnazza ML and D'Agata V: PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells. Neuropeptides 44: 45-51, 2009.
9. Sokoloff P, Giros B, Martres MP, Bouthenet ML and Schwartz JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151, 1990. (Pubitemid 20315872)
10. Bunzow JR, Van Tol HH, Grandy DK, et al: Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783-787, 1988.
11. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB and Civelli O: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991. (Pubitemid 21912282)
12. Sibley DR, Monsma FJ Jr, McVittie LD, Gerfen CR, Burch RM and Mahan LC: Molecular neurobiology of dopamine receptor subtypes. Neurochem Int 20: S17-S22, 1992.
13. Maggio R and Millan MJ: Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10: 100-107, 2010.
14. Bongarzone ER, Howard SG, Schonmann V and Campagnoni AT: Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. J Neurosci 18: 5344-5353, 1998.
15. Ohta K, Kuno S, Inoue S, Ikeda E, Fujinami A and Ohta M: The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci 291: 12-16, 2010.
16. Rosin C, Colombo S, Calver AA, Bates TE and Skaper SD: Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 52: 336-343, 2005.
17. 2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 372: 257-266, 2006.
18. Donarum EA, Halperin RF, Stephan DA and Narayanan V: Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex. BMC Neurosci 8: 7-22, 2006.
19. Forloni G, Angeretti N, Chiesa N, Monzoni E, Salmona M, Bugiani O and Tagliavini F: Neurotoxicity of a prion protein fragment. Nature 362: 543-546, 1993.
20. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008. (Pubitemid 351818697)
21. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
22. Pascale A, Fortino I, Covoni S, Trabucchi M, Wetsel WC and Battaini F: Functional impairment in protein kinase C by RACK1 (receptor for activated C kinase 1) deficiency in aged rat brain cortex. J Neurochem 67: 2471-2477, 1996.
23. Sonenberg N and Hinnebusch AG: Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731-745, 2009.
24. Levin VA, Panchabhai SC, Shen L, Kornblau SM, Qiu Y and Baggerly KA: Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res 9: 179-791, 2010.
25. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Rasi G and D'Agata V: PACAP and VIP prevent apoptosis in schwannoma cells. Brain Res 1241: 29-35, 2008.
26. Dasgupta B and Gutmann DH: Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci 25: 5584-5594, 2005.
27. Thomas SL, Deadwyler GD, Tang J, et al: Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. Biochem Biophys Res Commun 348: 971-980, 2006.
28. Imamura K, Takeshima T, Nakaso K, Ito S and Nakashima K: Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci Lett 440: 97-102, 2008.
29. Gu M, Iravani MM, Cooper JM, King D, Jenner P and Schapira AH: Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 91: 1075-1081, 2004.
30. Li A, Guo H, Luo X, Sheng J, Yang S, Yin Y and Zhou J: Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB J 20: 1263-1265, 2006.
31. Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K and Kuno S: Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 272: 18-22, 2000.